Natco Pharma hosts in-person investor meet on September 7

0 min read | Published on 02 Sept 2026, 09:04 PM |Updated on 02 Sept 2026, 09:08 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Natco Pharma hosts an in-person investor meet on September 7, 2026
The event runs from 10:00 am to 1:00 pm in Hyderabad
Antique Stock Broking organizes the group meeting
No UPSI will be discussed during the session

*this image is generated using AI for illustrative purposes only.

Natco Pharma has scheduled an in-person investor meeting on September 7, 2026. The event is organized by Antique Stock Broking and will be held in Hyderabad.

Meeting details

The company disclosed the schedule pursuant to Regulation 30 of the SEBI Listing Regulations. Officials will participate in the group meeting between 10:00 am and 1:00 pm.

Parameter	Details
Event	Investor meet (In-person and group)
Date	September 7, 2026
Time	10:00 am to 1:00 pm
Location	Hyderabad
Organizer	Antique Stock Broking

The schedule is subject to change due to exigencies on the part of the investor or the company. No Unpublished Price Sensitive Information (UPSI) is intended to be discussed during the interactions.

Historical Stock Returns for Natco Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.15%	-3.38%	-10.81%	-13.34%	-4.97%	-16.08%

What strategic updates regarding Natco Pharma's generic drug pipeline or biosimilar portfolio are investors likely to anticipate at this September 2026 meeting?

How might the company's performance in key international markets, particularly the US and Europe, influence the narrative presented during this investor interaction?

Are there any pending regulatory approvals or patent challenges that Natco Pharma may address as part of its forward-looking guidance?

Natco Pharma

View Company Insights

View All News

Natco Pharma promoter gifts 50,000 shares to niece

1 min read | Published on 26 Aug 2026, 03:03 PM |Updated on 26 Aug 2026, 03:03 PM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Promoter Durga Devi Nannapaneni gifted 50,000 equity shares to her niece
Transaction executed off-market on August 24, 2026
Promoter stake reduced from 1.98% to 1.95%
Total diluted share capital remains at 17,91,09,870 shares

*this image is generated using AI for illustrative purposes only.

Natco Pharma promoter Durga Devi Nannapaneni gifted 50,000 equity shares of the company to her niece, G. Kalajyothi. The off-market transaction was executed on August 24, 2026.

The company disclosed the transfer under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing was submitted to the BSE and NSE on August 26, 2026.

Shareholding Changes

Prior to the gift, Nannapaneni held 35,39,100 shares, representing a 1.98% stake in the company. Following the disposal, her holding reduced to 34,89,100 shares, or 1.95% of the total voting capital. The total diluted share capital of Natco Pharma remained unchanged at 17,91,09,870 shares.

Metric	Pre-Transaction	Post-Transaction	Change
Shares Held	35,39,100	34,89,100	-50,000
Stake Percentage	1.98%	1.95%	-0.03%
Transaction Type	Gift	Gift	Off-market

Regulatory Compliance

The disclosure confirms that no derivatives were traded by the promoter in connection with this transaction. The mode of acquisition for the recipient was specified as an off-market gift. No pledge or encumbrance details were reported for the transferred shares.

Historical Stock Returns for Natco Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.15%	-3.38%	-10.81%	-13.34%	-4.97%	-16.08%

Will G. Kalajyothi's acquisition of shares trigger any new insider trading disclosures or trading restrictions under SEBI regulations?

How might this internal restructuring of promoter holdings signal future changes in Natco Pharma's corporate governance or succession planning?

Could this off-market gift be interpreted by investors as a lack of confidence in near-term stock performance, potentially impacting market sentiment?

Natco Pharma

View Company Insights

View All News